CARE Series: Digital Therapeutics for Mental Health

Thursday, November 21, 2024, 12:00 PM - Sunday, November 21, 2027, 1:00 PM

AMA PRA Category 1 Credits™ (1.00 hours), ANCC Nursing Contact Hours (1.00 hours), CME-Designated Participation Credit (1.00 hours)

Reviews of:

• the evidence base for digital therapeutics for mental health and Substance Use Disorders.
• Prescription Digital Therapeutics: status nationally; developments by the pharmaceutical industry.
• real world implementation of digital therapeutics for mental health screening, treatment, and connection to services.
• engaging patients in mental health treatment augmented with digital therapeutics and in gauging usefulness.
• digital therapeutics summary: trends & immediate clinical applications.
  

 

Presenter

Lisa Marsch, Ph.D. 
Principal Investigator of the Northeast Node of the National Drug Abuse Treatment Clinical Trials Network
Director of the Center for Technology and Behavioral Health
Andrew G. Wallace Professor, Geisel School of Medicine at Dartmouth College

Dr. Lisa A. Marsch is the Director of the Dartmouth Center for Technology and Behavioral Health, a designated “Center of Excellence” supported by the National Institute on Drug Abuse at the National Institutes of Health. She is also the Director of the Northeast Node of the National Drug Abuse Treatment Clinical Trials Network, and the Andrew G. Wallace Professor within the Department of Psychiatry at the Geisel School of Medicine at Dartmouth College. The Dartmouth Center for Technology and Behavioral Health (CTBH) is a national interdisciplinary Center housed at Dartmouth and includes affiliates within the Geisel School of Medicine, the College of Arts and Sciences, The Thayer School of Engineering, and the Dartmouth Institute for Health Policy and Clinical Practice. CTBH also includes interdisciplinary partners across the U.S. and internationally. This Center uses science to inform the development, evaluation, and sustainable implementation of technology-based tools (that leverage web, mobile, sensing and/or social media approaches) for behavior change targeting a wide array of populations and health behaviors. These tools are designed to deliver engaging and effective health monitoring and health behavior interventions and to collectively lead to transformations in the delivery of science-based health care. In addition to directing this national Center, Dr. Marsch has personally been Principal Investigator on 40 grants, largely from the National Institutes of Health. She has led the development, evaluation and implementation of technology-based therapeutic tools for addiction treatment, HIV prevention, mental health, chronic pain management, substance abuse prevention, smoking cessation, and obesity. Her work in technology and addiction treatment has been particularly pioneering, as she is widely recognized as having led the development of the most widely tested and evidence-based mobile intervention for addiction treatment. She additionally maintains a priority focus on mentoring investigators, including junior faculty as well as students and post-doctoral fellows. Dr. Marsch publishes extensively and is a regular keynote speaker at national and international scientific meetings (including invited presentations at the White House, Congressional briefings, the World Bank, the US Surgeon General and the United Nations). She has served as a consultant to the Department of Mental Health and Substance Abuse at the World Health Organization. She served on the National Advisory Council to the National Institute on Drug Abuse at the National Institutes of Health. She serves on the Scientific Advisory Board of the Campus for Research Excellence and Technological Enterprise (CREATE) in Singapore.

1. Recall evidence of one impact of a digital therapeutic on health behavior or patient outcome
2. Describe steps for providers or patients to access one digital therapeutic tool.
3. Identify one aspect of a behavioral health treatment that could be augmented with a digital therapeutic.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours.

All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.
2. Register for the activity.
3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.
4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).
5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.
6. Complete and Submit the Evaluation.

Bibliographic Material

• Bickel WK, Marsch LA, Buchhalter AR, Badger GJ. Computerized behavior therapy for opioid-dependent outpatients: a randomized controlled trial. Exp Clin Psychopharmacol. 2008 Apr;16(2):132-43. doi: 10.1037/1064-1297.16.2.132. PMID: 18489017; PMCID: PMC2746734.
  
  
• Campbell CI, Chen CH, Adams SR, Asyyed A, Athale NR, Does MB, Hassanpour S, Hichborn E, Jackson-Morris M, Jacobson NC, Jones HK, Kotz D, Lambert-Harris CA, Li Z, McLeman B, Mishra V, Stanger C, Subramaniam G, Wu W, Zegers C, Marsch LA. Patient Engagement in a Multimodal Digital Phenotyping Study of Opioid Use Disorder. J Med Internet Res. 2023 Jun 13;25:e45556. doi: 10.2196/45556. PMID: 37310787; PMCID: PMC10337375
  
  
• Cárdenas P, Bartels SM, Cruz V, Gáfaro L, Uribe-Restrepo JM, Torrey WC, Castro SM, Cubillos L, Williams MJ, Marsch LA, Oviedo-Manrique DG, Gómez-Restrepo C. Perspectives, Experiences, and Practices in the Use of Digital Information Technologies in the Management of Depression and Alcohol Use Disorder in Health Care Systems in Colombia. Qual Health Res. 2020 May;30(6):906-916. doi: 10.1177/1049732320902460. Epub 2020 Feb 13. PMID: 32054418; PMCID: PMC7265234.
  
  
• Guarino H, Acosta M, Marsch LA, Xie H, Aponte-Melendez Y. A mixed-methods evaluation of the feasibility, acceptability, and preliminary efficacy of a mobile intervention for methadone maintenance clients. Psychol Addict Behav. 2016 Feb;30(1):1-11. doi: 10.1037/adb0000128. Epub 2015 Nov 30. PMID: 26618796; PMCID: PMC4924621.
  
  
• Maricich YA, Xiong X, Gerwien R, Kuo A, Velez F, Imbert B, Boyer K, Luderer HF, Braun S, Williams K. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder. Curr Med Res Opin. 2021 Feb;37(2):175-183. doi: 10.1080/03007995.2020.1846023. Epub 2020 Dec 7. PMID: 33140981.
  
  
• Marsch LA, Guarino H, Acosta M, Aponte-Melendez Y, Cleland C, Grabinski M, Brady R, Edwards J. Web-based behavioral treatment for substance use disorders as a partial replacement of standard methadone maintenance treatment. J Subst Abuse Treat. 2014 Jan;46(1):43-51. doi: 10.1016/j.jsat.2013.08.012. Epub 2013 Sep 21. PMID: 24060350; PMCID: PMC3839618.
  
  
• Marsch LA. Digital health data-driven approaches to understand human behavior. Neuropsychopharmacology. 2021 Jan;46(1):191-196. doi: 10.1038/s41386-020-0761-5. Epub 2020 Jul 12. PMID: 32653896; PMCID: PMC7359920.
  
  
  

US FDA GUIDANCE DOCUMENT 

 Policy for Device Software Functions and Mobile Medical Applications
Guidance for Industry and Food and Drug Administration Staff
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-device-software-functions-and-mobile-medical-applications

Resource

The Center for Technology and Behavioral Health at Dartmouth
https://www.c4tbh.org

 

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
[email protected]

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.